Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers

American Journal of Geriatric Cardiology

Volumn 10, Issue 1, 2001, Pages 50-54

  Liao, Wei‐chi ^a   Vesterqvist, Ole ^a   Manning, James ^a   Hammett, Janis L ^a   Ferreira, Irene M ^a   Meier, Alan ^a   Davis, Kathy D ^a   Hutman, H Wayne ^a,b  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b South Florida Bioavailability Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; OMAPATRILAT; PEPTIDE; PROTEINASE; VASOPEPTIDASE INHIBITOR;

ADULT; AGED; AGING; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR AGENTS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIDINES; REFERENCE VALUES; SEX FACTORS; THIAZEPINES;

EID: 0034815209     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2001.90856.x     Document Type: Article

References (21)

1. Effects of omapatrilat in low, normal, and high renin experimental hypertension
2. Pharmacodynamic effects of dual neutral endopeptidaseangiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans
3. The natriuretic-peptide family
4. Vasopeptidase inhibition: A new concept in blood pressure management
5. Pharmacodynamic effects of multiple doses of omapatrilat in healthy subjects
6. Marked elevation in plasma renin activity (PRA) in response to omapatrilat in healthy, normotensive males
7. Omapatrilat, a novel vasopeptidase inhibitor, reduces blood pressure in normotensive subjects
8. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment
9. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril
10. The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: A pilot study
11. Antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril
12. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor
13. Antihypertensive dose response of omapatrilat, a vasopeptidase inhibitor, in mild to moderate hypertension
14. Omapatrilat, a vasopeptidase inhibitor, is an effective antihypertensive agent in mild to moderate hypertension
15. Omapatrilat, a vasopeptidase inhibitor, produces long-term beneficial haemodynamic and neurohormonal effects in heart failure
16. Cardiac, renal, and endocrine effects of three month treatment of chronic heart failure with the vasopeptidase inhibitor, omapatrilat
17. Atrial natriuretic peptide and blood pressure in a population-based sample
18. Belmin J, Levy BI, Michel JB, Changes in the renin-angiotensin-aldosterone axis in later life
19. Cardioprotective mechanisms of ACE inhibition
20. C-type natriuretic peptide: The endothelial component of the natriuretic peptide system
21. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes